LIXT
$2.74-0.21 (-7.12%)
Market ClosedAs of Mar 20, 8:00 PM UTC
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.74
Potential Upside
5%
Whystock Fair Value$2.88
Price
UndervaluedFair ValueOvervalued
Fundamentals
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$23.85M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-83.13%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
10.42
